Yale researchers announced on April 2, 2026 that they've identified several FDA-approved drug candidates that reverse disrupted behaviors in zebrafish carrying mutations linked to autism. The team screened 774 drugs against zebrafish with mutations in two autism risk genes (SCN2A and DYRK1A) and published their findings in the Proceedings of the National Academy of Sciences.

What the Study Found

The Yale team created a database of 520 FDA-approved drugs and their effects on basic behaviors in zebrafish larvae. They then tested how these drugs affected zebrafish carrying mutations in SCN2A and DYRK1A, two genes strongly associated with autism spectrum disorder in humans.

Levocarnitine emerged as a top candidate. This compound, which transports fatty acids into mitochondria for energy production, reversed dysregulated sleep and sensory processing behaviors in zebrafish with both gene mutations. According to the study, levocarnitine also corrected disrupted lipid metabolism and abnormal brain activity patterns in the zebrafish models.

The researchers identified additional drug candidates specific to each gene mutation. Estropipate, an estrogen receptor agonist, suppressed behaviors linked to SCN2A mutations. Paclitaxel, a microtubule inhibitor already used in cancer treatment, showed promise for DYRK1A-related behaviors.

Why This Matters for Families

Drug development timelines for autism treatments typically span decades. By screening FDA-approved drugs that have already cleared safety trials, researchers can potentially accelerate the path to clinical testing in humans. If a drug is already approved for another condition, doctors may prescribe it off-label while formal autism trials proceed.

The focus on specific genetic mutations means families who know their child carries an SCN2A or DYRK1A mutation may eventually have access to more targeted treatment options. About 1-2% of autism cases involve SCN2A mutations, and DYRK1A mutations are associated with intellectual disability that often co-occurs with autism.

The research team also released an open-source searchable database of all drug profiles, making their findings accessible to other researchers working on autism treatments.

What Changed in How Researchers Study Autism Drugs

Traditional drug discovery for neurological conditions relies on mouse models, which are expensive and time-consuming. Zebrafish offer several advantages: their brains share fundamental structures with humans, they develop rapidly, and researchers can screen hundreds of drugs simultaneously.

The Yale study builds on previous zebrafish work that identified clemizole as a treatment candidate for Dravet syndrome, a severe form of epilepsy. That compound moved to human trials after showing promise in zebrafish models.

What Families Can Do Now

If your child has autism, these steps can help you stay connected to this research:

• Ask your child's neurologist whether genetic testing has been done. If not, discuss whether testing for autism risk genes like SCN2A or DYRK1A would be appropriate.
• If your child has a known SCN2A or DYRK1A mutation, ask the neurologist about monitoring research developments from this study and whether any identified drug candidates could be considered for off-label use.
• Check the Simons Foundation Autism Research Initiative (SFARI) for updates on clinical trials involving repurposed drugs for autism.
• Review the Yale team's open-source database when it becomes publicly available through their research publications.

Timeline and Next Steps

The study is published as of April 2, 2026. The research team has not announced specific timelines for human clinical trials, but the identification of already-approved drugs shortens the usual pathway from discovery to testing in children.

Families should expect that any drugs identified in this zebrafish screen will require further validation in mammalian models and safety trials before reaching clinical use for autism. The advantage is that safety profiles for these drugs already exist for their approved uses.

The full study is available at PNAS. Additional coverage appears on Medical Xpress.